Search

everythinglearnresearchcommunity

for

Search:↓

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Higher cholesterol levels increase aggressive prostate cancer risk.

Male pattern baldness may predict prostate cancer risk.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Serum triglyceride levels are not linked to prostate cancer risk.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.

AGA affects many, progresses differently, and early treatment is crucial.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

The document concludes that understanding hair follicle histology and the hair cycle is crucial for diagnosing alopecia.

Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.